Policy & Regulation
Solvonis reports positive bridging data for SVN-002 ahead of planned US Phase 2b
22 June 2026 - Biopharmaceutical company Solvonis Therapeutics plc (LSE: SVNS) on Monday reported positive pharmacokinetic data from a preclinical bridging study supporting the development of SVN-002,...
uniQure reports initial six‑month data from first AMT‑260 dose cohort
19 June 2026 - Dutch-American gene therapy company uniQure N.V. (NASDAQ: QURE) on Friday released initial six-month follow-up data from the first, low-dose cohort in its Phase I/IIa trial of AMT-260 f...
Incyte Japan wins approval for Minjuvi combination therapy in relapsed or refractory DLBCL
19 June 2026 - Incyte Biosciences Japan G.K., part of global biopharmaceutical company Incyte (Nasdaq:INCY), announced on Friday that Japan's Ministry of Health, Labour and Welfare has approved M...
Teijin and Merz secure Japanese approval for additional XEOMIN indications
19 June 2026 - Teijin Pharma Limited, part of Japanese technology holding company Teijin Group (TSE:3401), and Merz Therapeutics GmbH, part of Germany's Merz Group, announced on Friday that Japan...
Alvotech raises USD165m in public offering and private placement
19 June 2026 - Biotechnology company Alvotech (NASDAQ:ALVO) announced on Thursday the closing of its underwritten public offering of 26,066,667 of its ordinary shares at an offering price of USD3.75 p...
Oncoinvent reports recruitment milestone in Phase 2 study of Radspherin in ovarian cancer
19 June 2026 - Oncoinvent ASA (Euronext Growth Oslo:ONCIN), a Norway-based clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, announced on Thursday that its...